In view of the differences in LGR5 expression as well as the multifarious differences in high- and low-grade glioma [2], we divided all glioma patients into a low-grade glioma (LGG, WHO I and II) group and a high-grade glioma (HGG, WHO III and IV) group. Here, LGR5 is linked to central nervous system cancer.